It is under EMA new informed consent application, thus should be the same product as Relvar Ellipta with same ATC code. CHMP gave positive opinion on identical product UMEC/VI as Anoro and Laventair last month:
So my guess is GSK wants to market each of these two products, FF/VI and UMEC/VI, as two different brand products in EU, probably in different territories. They filed two applications simultaneously for UMEC/VI obviously, filed FF/VI under new informed consent application after Relvar Ellipta's approval.
Market Data 
Markets 
AI
